12 Week Study of Anti-Viral Effect of Oral UT-231B in Non-cirrhotic Hepatitis C Patients who have Failed Interferon-based Therapy.
NCT00069511
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
72
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis C
Interventions
DRUG:
UT-231B
Sponsor
United Therapeutics